FDA Grants Orphan Drug Status for Quark's QPI-1002 for the Prophylaxis of Delayed Graft Function in Kidney Transplant Patients

Tuesday, February 16, 2010 General News
Email Print This Page Comment
Font : A-A+

Quark Pharmaceuticals, Inc.

The Ruth Group (investors / media)

Juliana Friedman

Sara Pellegrino / Janine McCargo

+972 89 30 5111

(646) 536-7002 / 7033

jfriedman@quarkpharma.com

spellegrino@theruthgroup.com

jmccargo@theruthgroup.com



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook